47,212 Shares in Sanofi (NASDAQ:SNY) Purchased by JPL Wealth Management LLC

JPL Wealth Management LLC bought a new position in shares of Sanofi (NASDAQ:SNY) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 47,212 shares of the company’s stock, valued at approximately $2,277,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. HBK Sorce Advisory LLC raised its holdings in shares of Sanofi by 10.1% in the fourth quarter. HBK Sorce Advisory LLC now owns 4,267 shares of the company’s stock valued at $206,000 after purchasing an additional 391 shares during the last quarter. Avantax Advisory Services Inc. lifted its position in Sanofi by 23.4% during the fourth quarter. Avantax Advisory Services Inc. now owns 44,507 shares of the company’s stock worth $2,147,000 after purchasing an additional 8,439 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Sanofi by 30.7% in the fourth quarter. Farther Finance Advisors LLC now owns 3,739 shares of the company’s stock worth $180,000 after acquiring an additional 878 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Sanofi by 2.1% in the fourth quarter. Sequoia Financial Advisors LLC now owns 21,003 shares of the company’s stock worth $1,013,000 after acquiring an additional 425 shares during the last quarter. Finally, HighTower Advisors LLC lifted its holdings in shares of Sanofi by 3.4% in the fourth quarter. HighTower Advisors LLC now owns 91,071 shares of the company’s stock worth $4,392,000 after acquiring an additional 2,971 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Stock Performance

Shares of SNY opened at $57.69 on Thursday. The stock has a 50-day moving average price of $53.27 and a 200-day moving average price of $52.81. The company has a market cap of $146.41 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.